ID: ALA54057

Max Phase: Preclinical

Molecular Formula: C24H28N2O5S2

Molecular Weight: 488.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cccc(Sc2c(NS(=O)(=O)c3ccc(C(C)(C)C)cc3)noc2CCCC=O)c1

Standard InChI:  InChI=1S/C24H28N2O5S2/c1-24(2,3)17-11-13-20(14-12-17)33(28,29)26-23-22(21(31-25-23)10-5-6-15-27)32-19-9-7-8-18(16-19)30-4/h7-9,11-16H,5-6,10H2,1-4H3,(H,25,26)

Standard InChI Key:  KTTOCKMTBJPGAX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 488.63

Molecular Weight (Monoisotopic): 488.1440

AlogP: 5.45

#Rotatable Bonds: 10

Polar Surface Area: 98.50

Molecular Species: ACID

HBA: 7

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 5.65

CX Basic pKa:

CX LogP: 5.13

CX LogD: 4.24

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.30

Np Likeness Score: -0.89

References

1. Kanda Y, Takahashi T, Araki Y, Konoike T, Mihara S, Fujimoto M..  (2000)  Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.,  10  (16): [PMID:10969989] [10.1016/s0960-894x(00)00366-8]

2. Boss C, Bolli MH, Gatfield J..  (2016)  From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.,  26  (15): [PMID:27321813] [10.1016/j.bmcl.2016.06.014]

Source

Source(1):

• Scientific Literature